ResMed/$RMD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Ticker
$RMD
Sector
Primary listing
NYSE
Employees
10,600
Headquarters
Website
ResMed Metrics
BasicAdvanced
$36B
25.48
$9.77
0.83
$2.19
0.96%
Price and volume
Market cap
$36B
Beta
0.83
52-week high
$293.81
52-week low
$199.92
Average daily volume
1M
Dividend rate
$2.19
Financial strength
Current ratio
2.888
Quick ratio
1.825
Long term debt to equity
9.091
Total debt to equity
13.826
Dividend payout ratio (TTM)
22.31%
Profitability
EBITDA (TTM)
1,938.4
Gross margin (TTM)
60.69%
Net profit margin (TTM)
27.35%
Operating margin (TTM)
33.52%
Effective tax rate (TTM)
17.40%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
14.18%
Return on equity (TTM)
25.41%
Valuation
Price to earnings (TTM)
25.479
Price to revenue (TTM)
6.939
Price to book
5.94
Price to tangible book (TTM)
13.84
Price to free cash flow (TTM)
20.769
Free cash flow yield (TTM)
4.81%
Free cash flow per share (TTM)
11.986
Dividend yield (TTM)
0.88%
Forward dividend yield
0.96%
Growth
Revenue change (TTM)
9.36%
Earnings per share change (TTM)
29.59%
3-year revenue growth (CAGR)
13.20%
10-year revenue growth (CAGR)
11.89%
3-year earnings per share growth (CAGR)
22.31%
10-year earnings per share growth (CAGR)
14.74%
3-year dividend per share growth (CAGR)
8.81%
10-year dividend per share growth (CAGR)
6.75%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
Bulls say / Bears say
ResMed delivered robust Q4 FY2025 results with 10% year-over-year revenue growth, a 230 bps expansion in non-GAAP gross margin, and 23% non-GAAP EPS growth, underscoring strong demand and operational efficiency (ResMed Press Release).
Adoption of GLP-1 weight loss therapies has proven a tailwind, with GLP-1 users exhibiting 11% higher CPAP initiation and resupply rates, highlighting a new growth driver for ResMed’s mask and device business (Barron’s).
The acquisition of VirtuOx in May 2025 broadens ResMed’s digital health ecosystem by adding at-home diagnostic testing capabilities, enhancing patient access and strengthening its virtual care and connected device offerings (ResMed News).
Persistent supply chain disruptions—including semiconductor shortages and air/sea transportation bottlenecks—continue to limit ResMed’s production capacity and delay product availability, pressuring near-term revenue potential (MedTech Dive).
A U.S. Commerce Department probe into medical device imports under Section 232 has introduced tariff uncertainty, prompting a one-day share drop of 4–11% for ResMed and heightening regulatory risks for its global supply chain (Reuters).
Regulatory headwinds from CMS, including a 2.93% reduction in Medicare Physician Fee Schedule rates effective January 1, 2025, and the scheduled expiration of telehealth flexibilities at year-end may curb OSA diagnosis rates and dampen device utilization (ResMed 10-K Filing).
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
ResMed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for ResMed stock?
ResMed (RMD) has a market cap of $36B as of November 05, 2025.
What is the P/E ratio for ResMed stock?
The price to earnings (P/E) ratio for ResMed (RMD) stock is 25.48 as of November 05, 2025.
Does ResMed stock pay dividends?
Yes, the ResMed (RMD) stock pays dividends to shareholders. As of November 05, 2025, the dividend rate is $2.19 and the yield is 0.96%. ResMed has a payout ratio of 22.31% on a trailing twelve-month basis.
When is the next ResMed dividend payment date?
The next ResMed (RMD) dividend payment is scheduled for December 18, 2025.
What is the beta indicator for ResMed?
ResMed (RMD) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.